|
11th Annual Conference Of The British HIV Association [BHIVA]20–23 April 2005, Burlington Hotel·Dublin·Ireland |
[AUTHOR(S):] J Fox, T Scriba, A Oxenius, R Phillips, M McClure, K Porter, J Weber, S Fidler
Department of Medicine, Imperial College, London, UK
BHIVA Conf 2005 Apr 20-23;11:O18
BACKGROUND: Antiretroviral treatment at HIV seroconversion has been associated with the preservation of HIV-specific CD4+ T-cell responses ordinarily lost without intervention. The longevity and clinical relevance of this is unknown.
AIMS: To compare the immunological outcome of receiving short course ART (SCART) at Primary HIV (PHI) with rate of decline in CD4 count and this with a natural history cohort (CASCADE).
METHODS: Seroconversion was identified by an evolving HIV antibody response, HIV PCR-DNA positive/antibody negative or HIV antibody positive with negative test within 6 months. Patients were offered SCART and followed monthly. HIV-specific CD4 T-cell frequencies were determined by interferon-γ ELISPOT analysis.
RESULTS: Of 105 subjects followed prospectively for 3 years, 90 chose SCART at PHI. Longitudinal data on 16/105 subjects over 4 years, showed 7/14 receiving SCART had maintained HIV-specific CD4+ T-helper responses compared to 1/2 who did not receive SCART. All were CCR5 delta 32 negative. There was no relationship between T-helper responses, CD4 count, and pVL. We report a more rapid decline in CD4 count compared with CASCADE.
DISCUSSION: Despite the preservation of HIV-specific CD4 T-helper responses in 50% of treated seroconverters no correlation with CD4 count or clinical progression was observed.
PRESENTING AUTHOR: J Fox
2005-04-20
O18
Copyright © 2005 - British HIV Association (BHIVA) Reproduction of this abstract (other than one copy for personal reference) must be cleared through the BHIVA Organising Secretariat 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD